Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer

NCT00305734 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

NIH

Sponsor class

Conditions

Recurrent Nasopharyngeal Cancer
Stage IV Nasopharyngeal Cancer

Interventions

DRUG: bortezomib
DRUG: gemcitabine hydrochloride
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)